NasdaqCM - Nasdaq Real Time Price USD

Adial Pharmaceuticals, Inc. (ADIL)

1.6100 -0.1200 (-6.94%)
At close: 4:00 PM EDT
1.6400 +0.03 (+1.86%)
After hours: 4:24 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Cary John Claiborne MBA CEO, President & Director 728.31k -- 1961
Dr. Bankole A. Johnson DSc, FRCPsych, M.D., M.Phil, Ph.D. Founder & Chief Medical Officer 435k -- 1960
Mr. Joseph A. M. Truluck M.B.A., MBA CFO, Treasurer & Secretary 358.49k -- 1978
Mr. Tony Goodman COO & Director 33k -- 1964
Mr. John R. Martin J.D. Chief Legal Officer -- -- --
Ms. Catherine Fratila Controller -- -- --

Adial Pharmaceuticals, Inc.

1180 Seminole Trail
Suite 495
Charlottesville, VA 22901
United States
434 422 9800 https://www.adialpharma.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
4

Description

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Corporate Governance

Adial Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 10, 2024 - May 14, 2024
Adial Pharmaceuticals, Inc. Earnings Call

Related Tickers

NKGN NKGen Biotech, Inc.
1.6100
-18.69%
 
PCSA Processa Pharmaceuticals, Inc.
2.1500
-11.52%
 
PALI Palisade Bio, Inc.
6.05
-2.89%
 
PHIO Phio Pharmaceuticals Corp.
0.6820
+1.34%
 
CADL Candel Therapeutics, Inc.
6.39
-0.62%
 
BPTH Bio-Path Holdings, Inc.
2.6800
+1.71%
 
PXMD PaxMedica, Inc.
0.7398
+5.06%
 
LGVN Longeveron Inc.
1.7500
+4.79%
 
MLEC Moolec Science SA
1.4500
+2.11%
 
ASLN ASLAN Pharmaceuticals Limited
0.4153
-7.30%